Arcturus Poised to Move Liver Drug, COVID-19 Vaccine Into Clinic

Messenger RNA drug developer Arcturus Therapeutics is ready to kick off its first-ever human trials this year, beginning clinical evaluation of its lead drug candidate and testing a vaccine designed to target the novel coronavirus.

The San Diego biotech on Monday announced it had received the FDA’s OK to enter into the clinic with ARCT-810, an investigational treatment for ornithine transcarbamylase (OTC) deficiency, a rare inherited disease that causes dangerous levels of ammonia to accumulate in the body.